Agios Pharmaceuticals, Inc.
38 Sidney Street
About Agios Pharmaceuticals, Inc.
>Agios is focused on discovering and developing novel investigational medicines to treat cancer and rare genetic metabolic disorders through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across both therapeutic areas, Agios has multiple first-in-class investigational medicines in clinical and/or preclinical development. All Agios programs focus on genetically identified patient populations, leveraging our knowledge of metabolism, biology and genomics. For more information, please visit the company's website at www.agios.com.
August 7, 2007
Founders: Lewis Cantley, Tak Mak, Craig Thompson, Shin-San Michael Su
CEO: David Schenkein
CMO (Medical): Chris Bowden
CSO (Scientific): Scott Biller
Please click here for Agios job opportunities.
Please click here for clinical trial information.
251 articles with Agios Pharmaceuticals, Inc.
Agios' New Data From Ivosidenib Phase I Dose-Escalation and Expansion Trial Demonstrate Durable Responses in Patients With IDH1m Relapsed or Refractory AML
The CR+CRh rate is the primary endpoint of the study.
Agios' Data From Phase I Studies of Ivosidenib or Enasidenib in Combination With Full Doses of Standard of Care Chemotherapy Demonstrate Tolerability and Preliminary Clinical Activity in Newly Diagnosed AML Patients With an IDH Mutation
The data were presented as part of the scientific program at the 59th American Society of Hematology Annual Meeting in Atlanta.
Agios Presents Updated Data from DRIVE PK Study Demonstrating AG-348 is Well-Tolerated and Results in Clinically Relevant, Rapid and Sustained Hemoglobin Increases in Patients with Pyruvate Kinase Deficiency
DRIVE PK is an ongoing global open-label, Phase 2, safety and efficacy trial evaluating AG-348 in 52 adult, transfusion-independent patients with PK deficiency.
Dr. Fouse previously served as president and chief operating officer of Celgene Corporation until April 2017.
Agios Presents Updated Phase I Data from Dose Expansion Cohort of Ivosidenib (AG-120) in Patients With IDH1 Mutant Positive Glioma
The data were presented today in an oral presentation at the Society for Neuro-Oncology Annual Meeting in San Francisco.
In addition, Agios highlighted select corporate milestones and preclinical and clinical data from its development programs.
A live webcast can be accessed under "Events & Presentations" in the Investors section of the company's website at www.agios.com.
Agios Release: New Data From Phase I/II Trial Of Oral IDHIFA (Enasidenib) Demonstrate Durable Complete Responses In Patients With IDH2 Mutant Relapsed Or Refractory AML
Agios Announces Updated Data From Fully Enrolled DRIVE PK Study Demonstrating AG-348’s Potential As The First Disease-Modifying Treatment For Patients With Pyruvate Kinase Deficiency
Agios Presents Phase I Data From Dose-Escalation And Expansion Cohorts Of AG-120 (Ivosidenib) In Patients With IDH1 Mutant Positive Cholangiocarcinoma
Thermo Fisher Scientific Signs Development Agreement With Agios For Next-Generation Sequencing Oncology Companion Diagnostic In Cholangiocarcinoma
Agios And Aurigene Discovery Technologies Limited Enter Into Exclusive License Agreement For Novel Small Molecules For Cancer Metabolism Target